Last updated: September 1, 2026
Ingenol mebutate, marketed as Picato by LEO Pharma, was a topical treatment for actinic keratosis. The product’s commercial trajectory ended after regulators identified an increased risk of cutaneous malignancies, including squamous cell carcinoma. The European Union suspended and later withdrew marketing authorization in 2020. The U.S. Food and Drug Administration requested withdrawal of Picato from the U.S. market in February 2020, and LEO Pharma discontinued the product globally.[1][2]
The asset has no meaningful current pharmaceutical market, no credible generic-launch opportunity in the United States, and no active growth thesis based on the former product. Its residual value is limited to historical licensing, regulatory, litigation, manufacturing, and intellectual-property analysis.
What was ingenol mebutate and how was Picato used?
Ingenol mebutate was a topical diterpene ester derived from the sap of Euphorbia peplus. Picato gel was approved for short-course treatment of actinic keratosis, a precancerous skin condition caused primarily by cumulative ultraviolet exposure.
The product was differentiated by brief treatment courses rather than prolonged daily application:
| Product attribute |
Picato characteristics |
| Active ingredient |
Ingenol mebutate |
| Brand |
Picato |
| Original developer |
LEO Pharma |
| Dosage form |
Topical gel |
| Main indication |
Actinic keratosis |
| U.S. strengths |
0.015% and 0.05% |
| Treatment duration |
Two or three consecutive daily applications, depending on treatment area |
| FDA approval |
January 2012 |
| Commercial status |
Withdrawn and discontinued |
| Current market status |
No active commercial market |
The U.S. label covered 0.015% gel for the face and scalp and 0.05% gel for the trunk and extremities. Treatment was intentionally short, which gave Picato a convenience advantage over therapies requiring weeks of application.[3]
When did ingenol mebutate lose exclusivity?
Ingenol mebutate lost commercial exclusivity through regulatory withdrawal rather than through ordinary generic erosion. The product became commercially nonviable after regulators concluded that its benefit-risk profile was unfavorable because of malignancy concerns.
Key exclusivity and regulatory timeline
| Date |
Event |
Commercial effect |
| 2006 |
LEO Pharma acquired rights to Picato from Peplin |
Established LEO as commercial sponsor |
| January 2012 |
FDA approved Picato for actinic keratosis |
U.S. commercial launch |
| 2013-2015 |
European and other-market approvals expanded availability |
International revenue opportunity |
| 2015 onward |
Postmarketing and clinical data raised concerns regarding skin cancer risk |
Prescribing pressure increased |
| December 2019 |
EMA safety review recommended suspension |
European sales halted |
| February 2020 |
FDA requested voluntary withdrawal |
U.S. commercial market ended |
| 2020 |
LEO Pharma discontinued Picato globally |
Revenue trajectory terminated |
The product therefore did not reach a conventional patent-cliff transition. Its commercial life was interrupted before a normal loss-of-exclusivity cycle could generate a large generic market.
What FDA and EMA actions ended the Picato market?
The FDA requested withdrawal after reviewing clinical-trial data showing a higher incidence of skin tumors in patients treated with ingenol mebutate compared with vehicle control. The FDA concluded that the product’s risks outweighed its benefits and advised patients to stop using Picato.[1]
The EMA’s Pharmacovigilance Risk Assessment Committee identified an increased risk of skin cancers and recommended suspension of the marketing authorization. The European Commission subsequently confirmed the suspension and withdrawal process.[2]
The regulatory action was commercially decisive for four reasons:
- The product treated a non-life-threatening condition.
- Several alternative therapies were available.
- The risk involved malignancy rather than a temporary tolerability issue.
- The product required physician and patient confidence for repeated dermatology use.
Once withdrawal occurred, price, convenience, and market-access advantages no longer mattered. The relevant commercial question shifted from market share to product discontinuation and liability exposure.
How did the financial trajectory of ingenol mebutate change?
Picato generated commercial revenue during the 2010s but entered decline before withdrawal. Public LEO Pharma reporting identified declining Picato sales in the period leading to the global discontinuation, although LEO’s financial disclosures did not establish a continuing post-2020 revenue stream for the product.[4]
Financial trajectory
| Phase |
Financial condition |
Main driver |
| Pre-launch |
Investment phase |
Clinical development, regulatory filings, manufacturing scale-up |
| 2012-2014 |
Growth phase |
New treatment option for actinic keratosis |
| 2015-2018 |
Maturity and pressure |
Safety scrutiny, competitive alternatives, reimbursement limits |
| 2019 |
Decline |
Regulatory review and reduced physician confidence |
| 2020 |
Revenue collapse |
U.S. withdrawal, European suspension, global discontinuation |
| 2021 onward |
No material product growth |
Residual obligations rather than commercial expansion |
The asset’s economic value was concentrated in the years immediately after launch. Unlike a product that loses exclusivity after a peak-sales period, Picato suffered a risk-driven termination. This eliminated the expected value of future indications, geographic expansion, formulation improvements, and lifecycle-management projects.
What revenue exposure did LEO Pharma face?
The direct exposure included:
- Loss of branded Picato sales.
- Inventory write-downs and product-discontinuation costs.
- Regulatory and pharmacovigilance expenses.
- Potential legal costs and product-liability exposure.
- Abandoned development and commercialization investments.
- Reduced value of associated manufacturing and supply arrangements.
LEO Pharma’s overall portfolio was diversified across dermatology products, so Picato’s withdrawal did not represent a company-wide revenue collapse. It did, however, remove a marketed asset and reduce the value of a product that had been acquired and developed specifically for global dermatology expansion.[4]
What patents protected ingenol mebutate and Picato?
Picato was protected by a combination of active-ingredient, formulation, use, and regulatory exclusivity rights. The commercial importance of these rights declined sharply after withdrawal.
Patent categories
Active-ingredient and composition patents
Early patents covered ingenol derivatives and pharmaceutical compositions containing them. These rights were relevant to the original development and formulation program, but their effective commercial value depended on the drug remaining authorized and marketable.
Formulation patents
Formulation protection could cover:
- Ingenol mebutate gel compositions.
- Concentration ranges.
- Vehicles and excipients.
- Stability characteristics.
- Topical delivery systems.
- Packaging and administration formats.
Formulation patents generally provide narrower protection than a broad active-ingredient patent. They can delay or complicate generic entry but do not overcome a regulatory finding that the reference product is unsafe.
Method-of-use patents
Method-of-use claims could cover treatment of actinic keratosis by topical administration of ingenol mebutate, including specific body sites and dosing schedules. These rights would have had commercial relevance in an ANDA or Paragraph IV dispute while Picato remained approved.
Regulatory exclusivity
Picato’s original FDA approval included the regulatory exclusivity associated with a new chemical entity. That period expired before the 2020 withdrawal. No current regulatory exclusivity protects an active U.S. market.
Patent expiry dates should be assessed from the relevant Orange Book and USPTO records for each listed patent, including patent-term adjustment and any patent-term extension. A single headline expiry date is not sufficient because formulation and method-of-use patents can expire at different times.
What is the Orange Book status of Picato?
Picato’s Orange Book relevance is now historical. The FDA Orange Book records approved drug products and listed patents, but an Orange Book listing does not preserve commercial value after the reference product is withdrawn for safety reasons.
The practical status is:
| Issue |
Current assessment |
| Reference product |
Withdrawn |
| Active U.S. marketing |
None |
| ANDA opportunity |
Commercially unattractive |
| Paragraph IV litigation |
No meaningful current pathway without an active reference-product market |
| Patent-listing value |
Primarily historical |
| Generic substitution |
Not a significant current market event |
A withdrawn reference drug can create technical and legal complications for an ANDA applicant, particularly where the withdrawal was safety-related. The larger barrier for ingenol mebutate is not patent enforcement. It is the absence of a viable approved commercial product and the regulatory burden associated with reproducing a product whose benefit-risk profile led to withdrawal.
Which companies challenged or competed with Picato?
Picato competed in the actinic-keratosis market with established topical and procedural treatments rather than with a single direct molecular substitute.
| Treatment |
Company or category |
Competitive position |
| 5-fluorouracil |
Multiple manufacturers |
Established topical therapy; longer treatment courses |
| Imiquimod |
Multiple manufacturers |
Immune-mediated topical therapy |
| Diclofenac sodium gel |
Multiple manufacturers |
Longer treatment duration; established use |
| Photodynamic therapy |
Dermatology providers |
Office-based procedural alternative |
| Cryotherapy |
Dermatology providers |
Lesion-directed treatment |
| Tirbanibulin |
Almirall |
Newer short-course topical competitor |
| Curettage and excision |
Dermatology providers |
Lesion-directed procedures |
The competitive risk was asymmetric. Picato’s short regimen was attractive, but physicians could switch patients to older therapies with longer safety histories. Once the malignancy signal emerged, alternative treatments gained share without requiring comparable development risk.
How strong was the patent estate for ingenol mebutate?
The patent estate was commercially moderate before the safety withdrawal and weak after it.
Pre-withdrawal assessment
The estate likely provided meaningful protection through:
- Composition and formulation claims.
- Topical dosing claims.
- Actinic-keratosis method-of-use claims.
- Regulatory exclusivity during the initial launch period.
- Manufacturing know-how and product-quality controls.
Its strength was limited by the narrow therapeutic field. Picato was a topical product for a specific dermatology indication, and a competitor could avoid individual claims by using another active ingredient, another formulation, or another treatment modality.
Post-withdrawal assessment
After withdrawal, patent strength became secondary. Even an unexpired formulation or method-of-use patent would have limited practical value because:
- The reference product was no longer commercially supported.
- The indication carried a regulatory safety history.
- Generic sponsors would face market demand and liability concerns.
- Physicians had established alternatives.
- New development would require a favorable regulatory strategy.
Patent barriers cannot restore the economic value of a discontinued drug when the principal obstacle is safety.
What generic entry risks exist for ingenol mebutate?
The probability of a conventional generic launch is low.
United States
A generic sponsor would face:
- A withdrawn reference product.
- Limited commercial demand.
- Safety-related regulatory scrutiny.
- Potential need for additional clinical or safety evidence.
- Product-liability exposure.
- Competition from approved alternatives.
A Paragraph IV challenge would have little strategic value without a viable branded market to capture. Patent litigation could occur in theory, but the commercial incentive is substantially weaker than for an active, high-revenue drug.
Europe
European generic entry is also commercially improbable because the marketing authorization was suspended and withdrawn after the EMA safety review. National regulators and prescribers would require a clear basis for reintroducing the active ingredient.
Emerging markets
Some jurisdictions may have different withdrawal histories, registration standards, or enforcement practices. That does not create a strong global opportunity. Local market access would still depend on the safety profile, physician acceptance, and availability of alternative actinic-keratosis therapies.
What manufacturing and intellectual-property barriers remain?
Manufacturing ingenol mebutate requires control of active-ingredient identity, purity, concentration, topical uniformity, stability, and packaging. These are manageable technical requirements for a qualified pharmaceutical manufacturer, but they do not create a standalone commercial opportunity.
Potential barriers include:
- Supply of qualified ingenol mebutate active pharmaceutical ingredient.
- Reproducible low-dose topical formulation.
- Stability under storage conditions.
- Batch-to-batch content uniformity.
- Microbiological quality of the gel.
- Demonstration of bioequivalence or pharmaceutical equivalence.
- Regulatory remediation for the malignancy signal.
- Product-liability and pharmacovigilance infrastructure.
Trade secrets and manufacturing know-how could remain relevant even after patent expiry. Their value is limited because the key commercial problem is product safety, not inability to manufacture the gel.
What licensing deals affected ingenol mebutate?
LEO Pharma acquired rights to Picato from Peplin in 2006. The deal gave LEO commercial control over the product and supported global development and commercialization.[5]
The transaction created value through:
- Access to a late-stage dermatology asset.
- Expansion of LEO’s actinic-keratosis portfolio.
- International commercialization rights.
- Potential for lifecycle expansion in topical dermatology.
The withdrawal converted the transaction into a poor realized-return investment. The economic loss included the upfront and milestone consideration, development costs, launch costs, and foregone future revenue. Public disclosures do not provide a complete transaction-level return analysis.
What litigation and settlement issues affected Picato?
The primary risk was regulatory and product-liability exposure rather than a sustained generic patent dispute. Patients and law firms pursued claims alleging injuries associated with Picato use, including skin cancer. The existence, size, and resolution of individual claims can vary by jurisdiction and proceeding.
The most material legal consequences were:
- Regulatory withdrawal.
- Patient warnings and physician communications.
- Potential product-liability claims.
- Evidence preservation and pharmacovigilance obligations.
- Increased cost of defending the discontinued product.
There was no widely reported settlement structure that restored commercial value or enabled continued sales. For investment and licensing analysis, litigation reserves and unresolved liability should be treated as potential residual obligations attached to the historical asset.
How does ingenol mebutate compare with competing actinic-keratosis drugs?
| Factor |
Ingenol mebutate |
5-Fluorouracil |
Imiquimod |
Tirbanibulin |
| Current status |
Withdrawn |
Marketed |
Marketed |
Marketed |
| Treatment duration |
Very short |
Usually longer |
Usually longer |
Short |
| Safety overhang |
Skin-cancer signal |
Known local reactions |
Known local and systemic immune effects |
Newer safety database |
| Generic pressure |
Irrelevant after withdrawal |
High or established |
High or established |
Brand-led competition |
| Commercial outlook |
None |
Mature |
Mature |
Active growth opportunity |
| Main advantage |
Convenience |
Clinical familiarity and cost |
Field treatment and established use |
Short regimen |
Picato’s original value proposition was convenience. Its safety signal removed that advantage from the commercial equation. Tirbanibulin occupies part of the short-course niche with a different active ingredient and a current regulatory position.
What is the future market outlook for ingenol mebutate?
The forward market outlook is effectively zero for the discontinued Picato product. A future return would require more than patent clearance or a new license. It would require a regulatory strategy capable of addressing the malignancy risk, a defensible benefit-risk case, physician acceptance, and substantial investment in safety evidence.
Potential residual value is limited to:
- Historical patent and regulatory intelligence.
- Defensive management of product-liability claims.
- Archival manufacturing know-how.
- Academic research into ingenol derivatives or related mechanisms.
- Potentially differentiated derivatives that do not reproduce the Picato safety profile.
A relaunch of the same product for actinic keratosis is commercially unlikely. The market has established alternatives, and the original clinical positioning did not justify the observed safety risk.
Key Takeaways
- Ingenol mebutate was marketed as Picato by LEO Pharma for actinic keratosis.
- FDA and EMA actions in 2020 ended the product’s commercial market.
- The withdrawal was driven by increased skin-cancer risk, not ordinary patent expiration.
- Picato’s revenue trajectory moved from launch growth to decline and then effectively zero after discontinuation.
- Patent, formulation, and method-of-use rights have limited residual value after regulatory withdrawal.
- A conventional U.S. generic launch is commercially unlikely.
- The competitive market has shifted toward 5-fluorouracil, imiquimod, diclofenac, photodynamic therapy, cryotherapy, and tirbanibulin.
- Future value depends on safety remediation or derivative technology, not on relaunching the original product.
FAQs about ingenol mebutate market and patents
Is Picato still available in the United States?
No. The FDA requested withdrawal in 2020, and LEO Pharma discontinued Picato.
Why was ingenol mebutate withdrawn?
Regulators identified an increased risk of skin cancers, including squamous cell carcinoma, and determined that the risks outweighed the benefits for actinic keratosis.
Can a generic company still launch ingenol mebutate?
A generic launch is technically conceivable in some jurisdictions, but the U.S. and European commercial opportunity is weak because the reference product was withdrawn for safety reasons.
Did Picato have orphan-drug exclusivity?
No. Picato was approved for actinic keratosis, which is not an orphan indication. Its protection came from standard patent and new-drug regulatory frameworks.
What drug replaced ingenol mebutate for short-course actinic-keratosis treatment?
Tirbanibulin is a marketed short-course topical option, while procedural treatments and established therapies such as 5-fluorouracil and imiquimod remain widely used.
References
-
U.S. Food and Drug Administration. (2020, February 19). FDA requests withdrawal of Picato (ingenol mebutate) gel from the market. https://www.fda.gov
-
European Medicines Agency. (2020). Picato: EMA recommends withdrawal of marketing authorisation. https://www.ema.europa.eu
-
U.S. Food and Drug Administration. (2019). Picato (ingenol mebutate) gel prescribing information. https://www.accessdata.fda.gov
-
LEO Pharma. (2020). Annual report 2019. LEO Pharma A/S.
-
LEO Pharma. (2006, November 13). LEO Pharma acquires worldwide rights to Picato from Peplin. LEO Pharma corporate release.
